SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. APGE, a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced two abstracts co-written with Apogee’s research…Read More
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology EADV Congress Apogee Therapeutics NASDAQAPGE
